- Conditions
- PCOS
- Interventions
- Metformin and Spironolactone
- Drug
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 13 Years to 21 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–21
of 21
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Transgenderism
- Interventions
- Transdermal patch, Pro-thrombotic markers, Metabolic markers, Hormone Profile, Daily Sublingual Tablet, BID Sublingual Tablet, Spironolactone
- Drug · Diagnostic Test
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 30 Years · Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Polycystic Ovary Syndrome, Puberty Disorders, Ovulation Disorder
- Interventions
- Spironolactone
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 13 Years to 19 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Diastolic Heart Failure, Heart Failure, Congestive
- Interventions
- Spironolactone, Placebo
- Drug
- Lead sponsor
- Wake Forest University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Melasma
- Interventions
- Spironolactone 50Mg Tablet, Spironolactone 100Mg Tablet, Spironolactone 200Mg
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- End Stage Renal Disease, Hemodialysis
- Interventions
- Spironolactone, L-arginine, Placebo
- Drug · Dietary Supplement
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Bioavailability Heathy Volunteers
- Interventions
- FDC (24 mg ER torsemide and 30 mg Spironolactone) without food, FDC (24 mg ER torsemide and 30 mg Spironolactone) with food
- Combination Product
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Vienna, Virginia
- Conditions
- ST Elevation Myocardial Infarction, Non ST Elevation Myocardial Infarction
- Interventions
- Colchicine, Spironolactone, SYNERGY Bioabsorbable Polymer Drug-Eluting Stent, Colchicine-Placebo, Spironolactone-Placebo
- Drug · Device
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7,264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 11
- States / cities
- Bakersfield, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
- Conditions
- Bioavailability Heathy Volunteers
- Interventions
- Torsemide and Spironolactone tablet, Torsemide Tablets and Spironolactone Tablets
- Drug
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Vienna, Virginia
- Conditions
- Congestive Heart Failure
- Interventions
- Spironolactone
- Drug
- Lead sponsor
- University of Toledo Health Science Campus
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Toledo, Ohio
- Conditions
- Atrial Fibrillation
- Interventions
- Placebo, Ramipril, Spironolactone
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Right Heart Failure, Pulmonary Hypertension
- Interventions
- Spironolactone and conivaptan
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Healthy Participants
- Interventions
- Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris, Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hyperkalemia, Resistant Hypertension
- Interventions
- Patiromer, Placebo, Spironolactone
- Drug
- Lead sponsor
- Relypsa, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Hollywood, Florida • Miami Lakes, Florida • Chicago, Illinois
- Conditions
- Type 2 Diabetic Nephropathy
- Interventions
- PF-03882845, Spironolactone, placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 6
- States / cities
- Chula Vista, California • San Diego, California • DeLand, Florida + 3 more
- Conditions
- Hypertension (HTN)
- Interventions
- Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
- Drug
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Vienna, Virginia
- Conditions
- Cardiovascular Diseases, Heart Diseases, Heart Failure, Congestive
- Interventions
- Spironolactone, Placebo
- Drug
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 3,445 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 155
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 120 more
- Conditions
- Hypertension
- Interventions
- spironolactone, amiloride
- Drug
- Lead sponsor
- VA Salt Lake City Health Care System
- Federal
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Spironolactone, Standard care
- Drug · Other
- Lead sponsor
- Uppsala University
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 38
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Tucson, Arizona + 34 more
- Conditions
- Preeclampsia, Gestational Hypertension
- Interventions
- spironolactone 25 mg orally once daily, Placebo tablet to match spironolactone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Pittsburgh, Pennsylvania
- Conditions
- Bioequivalence Study in Healthy Subjects, PK/PD
- Interventions
- 10 mg Torsemide tablet, 25 mg Aldactone (Spironolactone) tablet, FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet
- Drug
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Vienna, Virginia